MicroPort Endovascular MedTech Ltd (688016) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥46.79 Million ≈ $6.85 Million USD) by net assets (CN¥3.98 Billion ≈ $582.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688016 days of operational coverage to measure how many days the company can operate on defensive assets alone.
MicroPort Endovascular MedTech Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how MicroPort Endovascular MedTech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MicroPort Endovascular MedTech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FLEX LNG Ltd
NYSE:FLNG
|
0.040x |
|
Allied Gold Corporation
NYSE:AAUC
|
0.432x |
|
Shanghai Shyndec Pharmaceutical Co Ltd
SHG:600420
|
0.030x |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
-0.036x |
|
Digital China Information Service Co Ltd
SHE:000555
|
0.281x |
|
Compania Nationala de Transport al Energiei Electrice Transelectrica SA
RO:TEL
|
0.054x |
|
Sparebank 1 Nord-Norge
OL:NONG
|
0.132x |
|
Fulltech Fiber Glass
TWO:1815
|
0.023x |
Annual Cash Flow Conversion Efficiency for MicroPort Endovascular MedTech Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of MicroPort Endovascular MedTech Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688016 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
CN¥573.06 Million ≈ $83.86 Million |
0.066x | -32.01% |
| 2024-12-31 | CN¥3.82 Billion ≈ $559.35 Million |
CN¥373.60 Million ≈ $54.67 Million |
0.098x | -33.89% |
| 2023-12-31 | CN¥3.86 Billion ≈ $565.36 Million |
CN¥571.22 Million ≈ $83.59 Million |
0.148x | -22.81% |
| 2022-12-31 | CN¥1.74 Billion ≈ $255.00 Million |
CN¥333.76 Million ≈ $48.84 Million |
0.192x | -2.91% |
| 2021-12-31 | CN¥1.52 Billion ≈ $222.73 Million |
CN¥300.25 Million ≈ $43.94 Million |
0.197x | +11.95% |
| 2020-12-31 | CN¥1.23 Billion ≈ $180.57 Million |
CN¥217.44 Million ≈ $31.82 Million |
0.176x | +31.17% |
| 2019-12-31 | CN¥1.07 Billion ≈ $155.98 Million |
CN¥143.20 Million ≈ $20.96 Million |
0.134x | -72.82% |
| 2018-12-31 | CN¥216.16 Million ≈ $31.63 Million |
CN¥106.85 Million ≈ $15.64 Million |
0.494x | +34.01% |
| 2017-12-31 | CN¥188.02 Million ≈ $27.51 Million |
CN¥69.36 Million ≈ $10.15 Million |
0.369x | +51.03% |
| 2016-12-31 | CN¥123.38 Million ≈ $18.05 Million |
CN¥30.13 Million ≈ $4.41 Million |
0.244x | -- |
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more